Myriad Genetics Dividend

Dividend criteria checks 0/6

Myriad Genetics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.9%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$2.91
Dividend yield forecast in 3Y	0%

Recent dividend updates

No updates

Recent updates

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Mar 28

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Feb 02

Myriad Genetics receives expanded coverage in Japan for breast cancer diagnostic system

Aug 25

Are Investors Undervaluing Myriad Genetics, Inc. (NASDAQ:MYGN) By 50%?

Aug 05

Myriad Genetics Q2 2022 Earnings Preview

Aug 03

Myriad Genetics touts study results of GeneSight test on depression remission rates

Jul 12

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if MYGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MYGN's dividend payments have been increasing.

Dividend Yield vs Market

Myriad Genetics Dividend Yield vs Market

How does MYGN dividend yield compare to the market?
Segment	Dividend Yield
Company (MYGN)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.7%
Industry Average (Biotechs)	2.9%
Analyst forecast in 3 Years (MYGN)	0%

Notable Dividend: Unable to evaluate MYGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MYGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate MYGN's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MYGN has not reported any payouts.

Myriad Genetics Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Myriad Genetics, Inc. to Report Q1, 2024 Results on May 07, 2024

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Consensus EPS estimates upgraded to US$0.93 loss

Price target increased by 8.9% to US$24.50

Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024

Full year 2023 earnings: EPS misses analyst expectations

Myriad Genetics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Myriad Genetics' Strategic Growth Fuels Bullish Outlook

Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024

Myriad Genetics, Inc. (NasdaqGS:MYGN) agreed to acquire Select assets of Intermountain Precision Genomics.

Myriad Genetics, Inc. Announces Chief Financial Officer Changes

Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price

Consensus EPS estimates fall by 21%, revenue upgraded

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New minor risk - Shareholder dilution

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Myriad Genetics, Inc. Provides Financial Guidance for 2023 and 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP notifies of intention to sell stock

Myriad Genetics, Inc. Appoints Samraat S. Raha as Chief Operating Officer, Effective as of December 11, 2023

Myriad Genetics Appoints Sam Raha as Chief Operating Officer, Effective December 11, 2023

Myriad Genetics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Price target decreased by 8.2% to US$21.67

Bernstein Litowitz Berger & Grossmann LLP Proposes Settlement of Class Action Involving Persons Who Purchased or Acquired Myriad Genetics, Inc. Common Stock

Insufficient new directors

Consensus EPS estimates fall by 52%

Myriad Genetics Announces Enhancements to the Genesight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status

Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2023

Myriad Genetics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Myriad Genetics, Inc. Announces Inclusion of Breast Density to Myrisk(R) with Riskscore(R) Breast Cancer Risk Assessment

Independent Director notifies of intention to sell stock

Myriad Genetics, Inc. Appoints Adam Brufsky as Scientific Advisor

Consensus EPS estimates fall by 27%, revenue upgraded

Myriad Genetics, Inc. Revises Earnings Guidance for the Full Year of 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 7.7% to US$21.72

Calculating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Chief Operating Officer notifies of intention to sell stock

Chief Operating Officer notifies of intention to sell stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 24%

Executive VP notifies of intention to sell stock

Myriad Genetics, Inc. Hires Senior Leaders to Advance Commercial Growth Plans

Myriad Genetics, Inc. announces Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

High number of new directors

Price target decreased to US$20.44

Myriad Genetics Announces Urosuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-Driven Medical Information

Consensus EPS estimates fall by 103%

Price target decreased to US$22.19

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Myriad Genetics, Inc. (NasdaqGS:MYGN) acquired Gateway Genomics, LLC for approximately $110 million.

Myriad Genetics, Inc. Elects Paul M. Bisaro as New Board Member

High number of new directors

Myriad Genetics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Myriad: Trying To Find Its Footing In An Evolving Industry

Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer

Myriad Genetics receives expanded coverage in Japan for breast cancer diagnostic system

Price target increased to US$24.36

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2022

Are Investors Undervaluing Myriad Genetics, Inc. (NASDAQ:MYGN) By 50%?

Myriad Genetics Q2 2022 Earnings Preview

Myriad Genetics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Myriad Genetics touts study results of GeneSight test on depression remission rates

Myriad Genetics, Inc. Announces the Resignation of Dennis Langer as Director

Independent Director notifies of intention to sell stock

Myriad Genetics, Inc. Announces Executive Changes

Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022

Price target decreased to US$23.93

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Myriad Genetics, Inc. Provides Earnings Guidance for the Fiscal Year 2022

High number of new directors